Emerald Advisers LLC Sells 336,078 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Emerald Advisers LLC lowered its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 32.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 685,447 shares of the medical technology company’s stock after selling 336,078 shares during the quarter. Emerald Advisers LLC owned about 0.49% of Alphatec worth $3,811,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in ATEC. Vanguard Group Inc. increased its position in shares of Alphatec by 1.2% during the first quarter. Vanguard Group Inc. now owns 5,458,847 shares of the medical technology company’s stock worth $75,278,000 after purchasing an additional 64,648 shares in the last quarter. Point72 Asset Management L.P. increased its position in Alphatec by 65.2% during the 2nd quarter. Point72 Asset Management L.P. now owns 3,192,789 shares of the medical technology company’s stock valued at $33,365,000 after buying an additional 1,260,137 shares in the last quarter. Fred Alger Management LLC raised its stake in Alphatec by 0.8% in the second quarter. Fred Alger Management LLC now owns 2,638,303 shares of the medical technology company’s stock valued at $27,570,000 after buying an additional 21,078 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Alphatec by 23.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,630,244 shares of the medical technology company’s stock worth $27,486,000 after acquiring an additional 505,202 shares in the last quarter. Finally, First Turn Management LLC grew its stake in shares of Alphatec by 37.3% during the second quarter. First Turn Management LLC now owns 1,360,410 shares of the medical technology company’s stock worth $14,216,000 after acquiring an additional 369,792 shares during the last quarter. Institutional investors own 66.35% of the company’s stock.

Alphatec Stock Performance

Shares of ATEC stock opened at $8.11 on Monday. The stock has a market cap of $1.15 billion, a PE ratio of -6.34 and a beta of 1.31. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $17.34. The business has a 50-day simple moving average of $5.82 and a 200-day simple moving average of $8.62. The company has a quick ratio of 1.21, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Insider Buying and Selling at Alphatec

In other news, Director David M. Demski bought 50,000 shares of the business’s stock in a transaction dated Wednesday, August 21st. The stock was purchased at an average cost of $5.67 per share, with a total value of $283,500.00. Following the acquisition, the director now directly owns 288,441 shares in the company, valued at $1,635,460.47. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 22.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ATEC shares. Piper Sandler decreased their price objective on shares of Alphatec from $17.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Stifel Nicolaus lowered their price objective on shares of Alphatec from $19.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Lake Street Capital cut their target price on Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. Morgan Stanley cut Alphatec from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 1st. Finally, Barclays began coverage on Alphatec in a research note on Monday, July 8th. They set an “overweight” rating and a $19.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Alphatec currently has a consensus rating of “Moderate Buy” and an average price target of $17.00.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.